Co-Diagnostics Targets Ebola, TB Markets with Decentralized PCR Platform

  • Co-Diagnostics showcasing Co-Dx PCR platform and MTB test at WHX Labs Johannesburg Oct. 6-8, 2026.
  • Company developing Ebola assay for decentralized testing amid $887M U.S. government Ebola response funding.
  • Co-Dx PCR MTB test targets tuberculosis diagnostics in Africa, where TB causes 1.23M deaths annually.
  • Event supported by State Trade Expansion Program grant from World Trade Center Utah.

Co-Diagnostics is positioning itself at the intersection of two critical global health challenges: emerging infectious disease outbreaks like Ebola and the persistent tuberculosis epidemic in Africa. The company's focus on decentralized diagnostics aligns with international health priorities, particularly as governments allocate substantial funding to improve outbreak response capabilities. Success in this space could position Co-Diagnostics as a key player in molecular diagnostics for low-resource settings.

Regulatory Pathway
Whether Co-Diagnostics can secure FDA and other regulatory clearances for its PCR platform and associated tests.
Funding Success
The pace at which the company secures grant funding for its Ebola assay development.
Market Adoption
How effectively the company positions its decentralized testing solution in high-burden regions like Africa.